• Contact Us
  • Indexing
  • Submit Manuscript
  • Open Access
  • Journals
  • Home
  • ISSN: 2373-9436
    Early Online
    Volume 5, Issue 2
    Research Article
    Ayse Kubra Karaboga Arslan*, Ebru Qzturk, and Mukerrem Betul Yerer
    Lung adenocarcinoma is one of the most commonly occurring cancer types and it is the leading cause of cancer-related deaths worldwide. Vanadium compounds have different pharmacological effects and have cytotoxic properties. Aim of this study was by continuous monitoring to assay the cytotoxicity of vanadium pentoxide (V2O5) on human lung carcinoma cell line (A549) and human bronchial epithelial cell line (Beas-2b). Eight different concentrations of V2O5 between 2.5-40M were applied on the cells and xCELLigence Real Time Cell Analysis (RTCA) was conducted to evaluate the impedance alterations over the Cell index values. Our results suggest the idea that V2O5 causes toxicity both on A549 and Beas-2b. We observed a dose-dependent cytotoxicity at 15 M and higher doses in the A549 cells which might reveal its anticancer metallodrug potential. However, for Beas-2b cells although the cytotoxicity of V2O5 started after 5 M, after 10 M, the CI alterations reached a stable value at all doses applied, resulting in a maximum reduction of 50% in this healthy cells. Therefore these results revealed us that, 20 M V2O5 at which cytotoxicity is initiated or up to 40 M at which the IC50 level have been reached in A549 can also be used in Beas-2b since the maximum toxicity have been already reached at/over 10M. We demonstrated that in cytotoxicity assays, the xCELLigence system can be used to optimize parameters such as the exposure time and compound concentrations. This study is the known first study to show V2O5s effects at these concentrations on A549 and Beas-2b in a real-time manner.
    Jaikanth C, Indhumathi T, Prema Gurumurthy*, and Cherian KM
    Background: Recently, HMG-CoA reductase inhibitors are receiving larger importance in cancer therapeutics as they targets both metabolic and signal transduction platform. However, their functional role in targeting Triple negative breast cancer cells and its associated mechanism remains elusive.
    Methods: In this study, growth inhibitory activity of simvastatin on MDA-MB-468 cells was assessed by MTT assay and its apoptotic potential by Nexin staining. Further, we employed label free quantitative proteomic profiling using mass tandem spectroscopy to explore the differentially expressed proteins associated with its anticancer activity.
    Results: Treatment of MDA-MB-468 cells with increased concentrations of Simvastatin showed a remarkable growth inhibitory activity with the IC50 value of 9 g/ml. Further, Nexin staining of the treated cells clearly indicates that, Simvastatin induces apoptosis in MDA-MD-468 cells. In Label free quantitative proteomic profiling of Simvastatin treated and untreated cells, 74 differentially expressed proteins were identified of which, 43 were up regulated and 31 were down regulated. Gene ontology and KEGG pathway enrichment analysis exposed 18 potential pathways associated with Simvastatin treatment. These identified pathways were shown to be related with focal adhesion, tumor progression, metastasis and metabolic effects in cancer cells. Among the down regulated proteins HSP90-alpha, Filamin-A, Alpha actinin-4, Vimentin and Phosphoglycerate kinase 1 was significantly down regulated.
    Conclusion: These results imply that the application of Simvastatin is a possible new drug in the field of neoplasia to control growth and progression of breast carcinoma cells. Further our proteomic profiling reveals potential new drug targets for future drug development.
    Special Issue on Lung Cancer China
    Short Communication
    Wanqing Chen*, Rongshou Zheng, Hongmei Zeng and Siwei Zhang
    Cancer is an emerging health issue in China and many other countries of the world. Lung cancer is the first leading cancer diagnosed and cause of cancer death for many years in China with a rapid increasing trend during the past several decades [1,2]. The incidence rate of lung cancer in China was relatively higher and also increasing with a more rapid rate than in western countries. Lots of risk factors such as cigarette smoking, air pollution has been proved as the risk factor of the disease [3-6].
    Review Article
    Jingjing Liu, Ying Cheng*, Hui Li and Shuang Zhang
    Abstract: Small Cell Lung Cancer (SCLC) account for almost 15% of lung cancers, which is strongly associated with cigarette smoking. It has a high propensity for early metastatic dissemination. Since few improvements in treatment effectiveness have been seen over the past 30 years new treatment strategies for improving therapeutic effect were urgently needed. China is the second most populous in the world and has many smokers. The morbidity and mortality of lung cancer are higher than the worldwide average. Because the government didn't take effective measures for smoking cessation, so the morbidity of SCLC has no downward trend. The progresses of studies in SCLC are slowly, such as diagnose, treatment and translational medicine. In recent years, with the emphasis of the society and the public on early diagnosis and early treatment of tumors and the progress of medical diagnosis technology, Chinese scholars have made many attempts in the treatment and research of SCLC.
    Xiu-Yi Zhi1*, Xiao-Nong Zou2, Mu Hu1, Yuan Jiang3 and You-lin Qiao4
    Abstract: In recent decades the age-specific mortalities of lung cancer in China have been increased to 9 times in men and women and it become one of the most important public health issues. The high prevalence of smoking in men and more than 70% of nonsmokers, both men and women, could be the biggest contributable factor for those consequences. While the abundant evidence on the health risks of exposure to smoking were available in both international and domestic studies the awareness on the health hazards from tobacco use were quit low in Chinese peoples, even in the health providers. Changes in the contents and the process of the tobacco products in Chinese tobacco product markets were accompanied by increased numbers of the lung cancer cases, increased adenocarcinoma and decreased squamous cell carcinoma of the lung, rather than reducing the overall lung cancer cases. Those suggested that comprehensive smoking-free policy should be implemented in all public places and the process of smoking-free legislation should put forward to create the legal environment and provide effective protection for reducing the incidence of lung cancer. Popularized health education should be also enhanced to raise the public awareness on smoking hazards.
  • Current Issue Highlights
  • BRAT1 was originally identified as a BRCA1 interacting protein [1], however, subsequent studies showed that it also binds to ATM, DNA-PK, and SMC1,

    Mechanisms of detecting and repairing damaged DNA are conserved and controlled through the DNA damage response (DDR).

    JSciMed Central Peer-reviewed Open Access Journals
    10120 S Eastern Ave, Henderson,
    Nevada 89052, USA
    Tel: (702)-751-7806
    Toll free number: 1-800-762-9856
    Fax: (844)-572-4633 (844-JSCIMED)
    E-mail: cancerbiology@jscimedcentral.com
    1455 Frazee Road, Suite 570
    San Diego, California 92108, USA
    Tel: (619)-373-8720
    Toll free number: 1-800-762-9856
    Fax: (844)-572-4633 (844-JSCIMED)
    E-mail: cancerbiology@jscimedcentral.com
    About      |      Journals      |      Open Access      |      Special Issue Proposals      |      Guidelines      |      Submit Manuscript      |      Contacts
    Copyright © 2016 JSciMed Central® All Rights Reserved
    Creative Commons Licence Open Access Publication by JSciMed Central® is licensed under a Creative Commons Attribution 4.0 International License.
    Based on a work at https://jscimedcentral.com/. Permissions beyond the scope of this license may be available at https://creativecommons.org/.